

Universal Biosensors Inc  
ARBN 121 559 993

1 Corporate Avenue  
Rowville VIC 3178  
Australia

Telephone +61 3 9213 9000  
Facsimile +61 3 9213 9099  
Email [info@universalbiosensors.com](mailto:info@universalbiosensors.com)  
[www.universalbiosensors.com](http://www.universalbiosensors.com)



**Universal Biosensors**

30 September 2016

## **UBI receives \$9.36M under the R&D Tax Incentive**

Universal Biosensors (ASX:UBI) today announced it has received \$9.36M in cash under the R&D Tax Incentive for the 2015 financial year noting it had recorded a receivable of \$9.20M in its financial statements.

The R&D Tax Incentive is an Australian Government program developed to assist businesses recover some of the costs of undertaking research and development. Under this program companies receive cash refunds for 45% of eligible expenditure on research and development.

### **Ends**

Enquiries:  
Mr. Satesh Balak  
Mr. Andrew Denver  
+61 3 9213 9000

### **About Universal Biosensors**

For additional information regarding Universal Biosensors, refer to: <http://www.universalbiosensors.com/>.

Universal Biosensors is a specialist medical diagnostics company, founded in 2001, that is focused on the development, manufacture and commercialisation of a range of in vitro diagnostic tests for point-of-care use. These tests capitalise on a technology platform which uses a novel electrochemical cell that can be adapted for multiple analytes and provide for enhanced measurements in whole blood.

### **Forward-Looking Statements**

The statements contained in this release that are not purely historical are forward-looking statements within the meaning of the US Securities Exchange Act of 1934. Forward-looking statements in this release include statements regarding our expectations, beliefs, hopes, intentions or strategies. All forward-looking statements included in this release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Our actual results could differ materially from our current expectations. We cannot assure you when, if at all, the proposals outlined in this release will occur, and the terms of any such proposal are subject to change. Factors that could cause or contribute to such differences include, but are not limited to, factors and risks disclosed from time to time in reports filed with the SEC.